GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:0051099111 | Esophagus | ESCC | positive regulation of binding | 122/8552 | 173/18723 | 2.79e-11 | 9.45e-10 | 122 |
GO:004339320 | Esophagus | ESCC | regulation of protein binding | 135/8552 | 196/18723 | 3.69e-11 | 1.22e-09 | 135 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:2000278110 | Esophagus | ESCC | regulation of DNA biosynthetic process | 81/8552 | 106/18723 | 9.81e-11 | 2.96e-09 | 81 |
GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
GO:000646920 | Esophagus | ESCC | negative regulation of protein kinase activity | 140/8552 | 212/18723 | 1.53e-09 | 3.56e-08 | 140 |
GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:001081020 | Esophagus | ESCC | regulation of cell-substrate adhesion | 144/8552 | 221/18723 | 3.55e-09 | 7.45e-08 | 144 |
GO:0001890110 | Esophagus | ESCC | placenta development | 98/8552 | 144/18723 | 4.46e-08 | 8.11e-07 | 98 |
GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
GO:005197217 | Esophagus | ESCC | regulation of telomerase activity | 39/8552 | 47/18723 | 1.48e-07 | 2.35e-06 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEN1 | SNV | Missense_Mutation | novel | c.676N>A | p.Leu226Met | p.L226M | O00255 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MEN1 | SNV | Missense_Mutation | | c.1817C>G | p.Ser606Cys | p.S606C | O00255 | protein_coding | deleterious(0.01) | possibly_damaging(0.82) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEN1 | SNV | Missense_Mutation | | c.323G>C | p.Arg108Pro | p.R108P | O00255 | protein_coding | tolerated(0.07) | possibly_damaging(0.7) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEN1 | SNV | Missense_Mutation | | c.1084G>C | p.Asp362His | p.D362H | O00255 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MEN1 | SNV | Missense_Mutation | rs377715802 | c.1040N>T | p.Ala347Val | p.A347V | O00255 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MEN1 | SNV | Missense_Mutation | | c.479N>T | p.Ser160Phe | p.S160F | O00255 | protein_coding | tolerated(1) | benign(0.009) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MEN1 | SNV | Missense_Mutation | | c.550G>A | p.Glu184Lys | p.E184K | O00255 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEN1 | deletion | Frame_Shift_Del | | c.1700_1706delNNNNNNN | p.Lys567SerfsTer24 | p.K567Sfs*24 | O00255 | protein_coding | | | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEN1 | deletion | Frame_Shift_Del | | c.225_229delNNNNN | p.Thr76LeufsTer39 | p.T76Lfs*39 | O00255 | protein_coding | | | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MEN1 | insertion | Frame_Shift_Ins | rs767319284 | c.1561_1562insC | p.Arg521ProfsTer15 | p.R521Pfs*15 | O00255 | protein_coding | | | TCGA-E9-A228-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | CHLORHEXIDINE HYDROCHLORIDE | CHLORHEXIDINE HYDROCHLORIDE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | FURAFYLLINE | FURAFYLLINE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TCMDC-123591 | CHEMBL588234 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | CYCLIRAMINE MALEATE | CYCLIRAMINE MALEATE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | METHYLENE BLUE | METHYLENE BLUE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TANNIC ACID | TANNIC ACID | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | SJ000029700 | CHEMBL591864 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TRIMETREXATE | TRIMETREXATE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TCMDC-124518 | CHEMBL527584 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TRACAZOLATE | TRACAZOLATE | |